- Home
- KNSA
as of 03-12-2026 3:42pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 3.4B | IPO Year: | 2018 |
| Target Price: | $55.29 | AVG Volume (30 days): | 574.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.75 | EPS Growth: | 225.00 |
| 52 Week Low/High: | $18.25 - $49.12 | Next Earning Date: | N/A |
| Revenue: | $677,564,000 | Revenue Growth: | 60.09% |
| Revenue Growth (this year): | 38.01% | Revenue Growth (next year): | 17.42% |
| P/E Ratio: | 61.77 | Index: | N/A |
| Free Cash Flow: | 136.4M | FCF Growth: | +436.82% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$45.91
Shares
36,722
Total Value
$1,686,157.82
Owned After
12,086
CHIEF MEDICAL OFFICER
Avg Cost/Share
$45.00
Shares
40,000
Total Value
$1,792,939.72
Owned After
89,261
Director
Avg Cost/Share
$45.00
Shares
2,690
Total Value
$121,050.00
Owned After
12,546
SEC Form 4
Director
Avg Cost/Share
$45.00
Shares
110
Total Value
$4,950.00
Owned After
12,546
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$43.29
Shares
17,845
Total Value
$772,254.22
Owned After
12,086
Director
Avg Cost/Share
$45.02
Shares
2,602
Total Value
$117,142.04
Owned After
12,546
SEC Form 4
Director
Avg Cost/Share
$45.27
Shares
12,528
Total Value
$567,142.56
Owned After
12,546
SEC Form 4
Director
Avg Cost/Share
$45.00
Shares
830
Total Value
$37,350.00
Owned After
12,546
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$41.89
Shares
12,000
Total Value
$502,680.00
Owned After
12,086
SEC Form 4
CHIEF OPERATING OFFICER
Avg Cost/Share
$41.56
Shares
12,048
Total Value
$500,714.88
Owned After
16,666
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 9, 2026 | Sell | $45.91 | 36,722 | $1,686,157.82 | 12,086 | |
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Mar 2, 2026 | Sell | $45.00 | 40,000 | $1,792,939.72 | 89,261 | |
| Quart Barry D | KNSA | Director | Feb 12, 2026 | Sell | $45.00 | 2,690 | $121,050.00 | 12,546 | |
| Quart Barry D | KNSA | Director | Feb 10, 2026 | Sell | $45.00 | 110 | $4,950.00 | 12,546 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Feb 9, 2026 | Sell | $43.29 | 17,845 | $772,254.22 | 12,086 | |
| Quart Barry D | KNSA | Director | Feb 4, 2026 | Sell | $45.02 | 2,602 | $117,142.04 | 12,546 | |
| Quart Barry D | KNSA | Director | Feb 3, 2026 | Sell | $45.27 | 12,528 | $567,142.56 | 12,546 | |
| Quart Barry D | KNSA | Director | Feb 2, 2026 | Sell | $45.00 | 830 | $37,350.00 | 12,546 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Jan 8, 2026 | Sell | $41.89 | 12,000 | $502,680.00 | 12,086 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Dec 15, 2025 | Sell | $41.56 | 12,048 | $500,714.88 | 16,666 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 24, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 24, 2026 · 100% conf.
1D
-1.78%
$42.72
Act: -1.70%
5D
-2.19%
$42.55
Act: +4.30%
20D
-2.34%
$42.48
Kiniksa Pharmaceuticals International, plc_February 24, 2026 0001730430false00017304302026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter)
England and Wales 001-730430 98-1795578
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
Kiniksa Pharmaceuticals International, plc 105 Piccadilly, Second Floor London, W1J 7NJ England, United Kingdom (781) 431-9100 (Address, zip code and telephone number, including area code of principal executive offices) Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA, 02421 (781) 431-9100 (Address, zip code and telephone number, including area code of agent for service) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Ordinary Shares $0.000273235 nominal value
KNSA
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On February 24, 2026, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the fiscal year ended December 31, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Kiniksa Pharmaceuticals International, plc, dated February 24, 2026
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
Date: February 24, 2026 By: /s/ Douglas Barry
Douglas Barry
Senior Vice President, Chief Legal Officer and Secretary
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
1D
-1.78%
$42.72
Act: -1.70%
5D
-2.19%
$42.55
Act: +4.30%
20D
-2.34%
$42.48
Kiniksa Pharmaceuticals International, plc_January 12, 2026 0001730430false00017304302026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter)
England and Wales 001-730430 98-1795578
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
105 Piccadilly, Second Floor London, W1J 7NJ England, United Kingdom (781) 431-9100 (Address, zip code and telephone number, including area code of principal executive offices) Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA, 02421 (781) 431-9100 (Address, zip code and telephone number, including area code of agent for service) 23 Old Bond Street, Floor 3 London, W1S 4PZ England, United Kingdom (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Ordinary Shares $0.000273235 nominal value
KNSA
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On January 12, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) issued a press release announcing, among other things, that (i) ARCALYST net product revenue was $677.5 million for the full year 2025 (unaudited), (ii) gross-to-net was 8.4% for the full year 2025 (unaudited) and (iii) as of December 31, 2025 it had $414.1 million of cash, cash equivalents and short-term investments and no debt (unaudited). A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Kiniksa Pharmaceuticals International, plc, dated January 12, 2026
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
Date: January 12, 2026 By: /s/ Douglas Barry
Douglas Barry
Senior Vice President, Chief Legal Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 28, 2025
Q3 2025 Earnings
8-KOct 28, 2025
false 0001730430
0001730430
2025-10-28 2025-10-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 28, 2025
Kiniksa Pharmaceuticals International, plc
(Exact name of Registrant as Specified in Its Charter)
England and Wales
001-730430
98-1795578
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
23 Old Bond Street, Floor 3
London, W1S 4PZ
England, United Kingdom
(Address of principal executive offices, including zip code)
(781) 431-9100
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which
registered
Class A Ordinary Shares, $0.000273235 nominal value
KNSA
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On October 28, 2025, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Description
99.1
Earnings Press Release issued by Kiniksa Pharmaceuticals International, plc, dated October 28, 2025
104
Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
Date: October 28, 2025 By: /s/ Douglas Barry
Douglas Barry
Senior Vice President, Chief Legal Officer and Secretary
Compare KNSA vs Leading Stocks
See how KNSA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.